The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
about
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupNeuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesNeurological immune reconstitution inflammatory response: riding the tide of immune recoveryProgressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarateMRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry StudyAnaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromesCerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyOutcome and survival of asymptomatic PML in natalizumab-treated MS patients.PML-IRIS during Fingolimod Diagnosed after Natalizumab DiscontinuationHeterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature.JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case studyCurrent and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.Concomitant granule cell neuronopathy in patients with natalizumab-associated PMLNatalizumab-Related Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Case Report Highlighting Clinical and MRI Features.Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod.Current management of relapsing-remitting multiple sclerosis.Immune reconstitution inflammatory syndrome associated with biologic therapy.Natalizumab in relapsing-remitting multiple sclerosis.Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions.MRI pattern in asymptomatic natalizumab-associated PML.Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?Laminar Cortical Hypointensities in Susceptibility-Weighted Imaging in a Case of Progressive Multifocal Leukoencephalopathy.To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.Critical updates in the 7th edition of the American Society for Apheresis guidelines.Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapyTransient gadolinium leakage in natalizumab-treated multiple sclerosis: Figure 1
P2860
Q26780412-99C357EC-4DD5-46E0-8F43-B947E1D7842CQ26781389-EA1976EB-B8D9-45E3-A8E9-C61902C65C7EQ28082309-2A373A56-ED7E-4FBC-A276-6C14B0061797Q28083338-20F070BB-B728-4D72-A50D-B96012BAB9B3Q30981999-EC0B4DD4-DE90-40B8-A1F9-50EB99E83E6DQ33810020-55B70A35-0DB4-4CFE-8459-62F3A062DE11Q33814485-9E55DFDF-8B70-41B8-B9D5-6AD05E3BAF61Q34324861-FDD9C2FE-32CC-4145-A1C5-99885B94125EQ34562841-BF4CCC07-937A-4365-BB1B-292BDC7393A5Q34650456-68AB1B0C-2D63-4E25-A5FC-7878FDFCED0FQ35314514-BB999F3C-DB24-44AF-9E8F-9A7494682A17Q35586120-D93C716F-B190-4BD0-8101-5BC7BB4B15C8Q36242324-6D37E609-3770-4EF2-B404-A73BC8110393Q36352813-149F5969-D8F5-42D5-8EA9-D9BDB813CD51Q36783871-571C032F-D684-48F0-92D7-44266FC14933Q37403424-0ECF3145-1CD4-4C7F-B9EB-8CAB000A4A28Q37475542-113E6F3B-BD97-4B55-BB0D-5D254DCAC12BQ38258818-71969F41-A242-49DD-93EC-D7F881272311Q38287572-1732A40E-9E06-4415-A3F7-CE3476E050F4Q38786252-858037E1-6D8F-4677-80A3-083207DEA298Q39211049-AE44F47C-E742-496E-8229-005A92D0215CQ40619670-8A9CB2F1-47BB-4476-B3C1-6AB28C04679EQ41126166-4A0AFE19-E9A3-4EB9-B8D4-1F31F4FAC34EQ41361912-669A734C-1804-4D6F-86E1-82812A3F8B2DQ41386664-D1150463-E78F-4D13-A2B2-E25910BF6203Q41455235-7D9680C0-1897-45B9-BA69-63410CD5F0E0Q41745436-10D4B8A1-73B0-4094-BCE1-89765493B510Q42226607-A3DB304A-19F0-4B89-B927-8B9C96F646E1Q42362984-3A459291-0F94-4C7C-AA96-211D6616A5F7Q47812653-4C771A91-7C8A-40E3-88E3-9F80AD339277Q48217985-6A4ABD06-1B60-4454-912C-FA7F3D63F6CFQ51846870-D24E299F-05EF-427F-B216-4246833C8465Q52150367-4416409C-74E1-49C0-B5BD-9A7820507F5CQ52659119-C613AC5A-B961-48BA-A559-BDD572952EE7Q57514485-0C16623D-BEF8-4614-98CA-DA976C2198D9Q57541973-5C91E75A-24C7-4103-9607-5086F7AA74BC
P2860
The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The chameleon of neuroinflamma ...... ultifocal leukoencephalopathy.
@ast
The chameleon of neuroinflamma ...... ultifocal leukoencephalopathy.
@en
type
label
The chameleon of neuroinflamma ...... ultifocal leukoencephalopathy.
@ast
The chameleon of neuroinflamma ...... ultifocal leukoencephalopathy.
@en
prefLabel
The chameleon of neuroinflamma ...... ultifocal leukoencephalopathy.
@ast
The chameleon of neuroinflamma ...... ultifocal leukoencephalopathy.
@en
P2093
P921
P356
P1476
The chameleon of neuroinflamma ...... ultifocal leukoencephalopathy.
@en
P2093
Diego Cadavid
Esther Sanchez
Joep Killestein
Marlieke de Vos
Mike P Wattjes
Nancy D Richert
Petur Snaebjornsson
P304
P356
10.1177/1352458513510224
P577
2013-11-05T00:00:00Z